TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30818765

Group type: EXPERIMENTAL
Intervention: Nitration using 25-30% HNO3 for 30-40 minutes at room temperature
Number of subjects: 0
Study: 28230607

Group type: EXPERIMENTAL
Intervention: Probiotic capsule (Lactobacillus acidophilus ATCC B3208, 3×10^10 CFU; Bifidobacterium lactis DSMZ 32269, 6×10^10 CFU; Bifidobacterium bifidum ATCC SD6576, 2×10^10 CFU; Lactobacillus rhamnosus DSMZ 21690, 2×10^10 CFU) for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study: 26388504

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 46
Study: 23263208

Group type: EXPERIMENTAL
Intervention: Group T (using ultrasound machine with onboard electronic tutorial)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group S (using standard ultrasound machine)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group T
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group S
Number of subjects: 35
Study: 22018124

Group type: EXPERIMENTAL
Intervention: Postplacental IUD
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed IUD
Number of subjects: 96
Study: 18430855

Group type: EXPERIMENTAL
Intervention: 64-MDCT
Number of subjects: 38

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 64-MDCT and MRI
Number of subjects: 38
Study: 16595276

Group type: EXPERIMENTAL
Intervention: 6- to 8-hour, 7-lesson education experience with food preparation and tasting (EFNEP)
Number of subjects: 5111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5111
Study: 14600570

Group type: EXPERIMENTAL
Intervention: Heat-dissociated p24 antigen (HD p24 Ag) assay
Number of subjects: 117

Group type: COMPARATOR
Intervention: HIV-1 RNA levels quantified by the Amplicor HIV-1 Monitor assay
Number of subjects: 117
Study: 10981842

Group type: EXPERIMENTAL
Intervention: Emphasizing aspects of identity that differentiate from the comparison standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9181519

Group type: EXPERIMENTAL
Intervention: Melatonin (100 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (0.625 mg/day)
Number of subjects: 7
Study: 1286524

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.125 mg twice weekly
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg twice weekly
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.75 mg twice weekly
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg twice weekly
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 4064569

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐8)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Combination of CCK‐like peptide, caerulein, and secretin
Number of subjects: 5
Study: 31905205

Group type: EXPERIMENTAL
Intervention: Saline solution (PosiFlush®, group A)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Heparin (Fibrilin®, group B)
Number of subjects: 241
Study: 30115086

Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pasteurized donor human milk (PDHM)
Number of subjects: 70
Study: 27179402

Group type: EXPERIMENTAL
Intervention: Trastuzumab + Docetaxel (Group A)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Docetaxel (Group B)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab (Group C)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Docetaxel (Group D)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Total Pathological Complete Response (all groups combined)
Number of subjects: 417
Study: 24811603

Group type: EXPERIMENTAL
Intervention: Midline catheter (POWERWAND®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PICC
Number of subjects: 0
Study: 22619886

Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.5 mcg twice weekly
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no oral calcitriol)
Number of subjects: 91
Study: 19560307

Group type: EXPERIMENTAL
Intervention: Adherence intervention based on Fisher & Fisher's Information‐Motivation‐Behavioral Skills Model
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ongoing fidelity monitoring with motivational interviewing
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Refill rate
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Adherence support from a consistent caring individual
Number of subjects: 73
Study: 17589949

Group type: EXPERIMENTAL
Intervention: Submucosal saline‐epinephrine injection (epinephrine group)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Normal saline injection (saline group)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 486
Study: 15610261

Group type: EXPERIMENTAL
Intervention: Mid-dilution hemodiafiltration (HDF) with Nephros OLpur MD 190 hemodiafilter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post-dilution hemodiafiltration (HDF) with conventional synthetic high-flux dialyzer
Number of subjects: 10
Study: 12175402

Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lignocaine infiltrated into the periprostatic nerve plexus bilaterally
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 11 mL of 2% lignocaine gel rectally
Number of subjects: 86

Group type: COMPARATOR
Intervention: Plain gel rectally
Number of subjects: 86

Group type: COMPARATOR
Intervention: Saline injection into the periprostatic nerve plexus
Number of subjects: 86
Study: 10206568

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (n = 19) with 12 weekly sessions
Number of subjects: 55

Group type: COMPARATOR
Intervention: Rheumatological treatment alone (Control group)
Number of subjects: 55
Study: 8582345

Group type: EXPERIMENTAL
Intervention: Oligonucleotide (CAC)5 fingerprinting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probes 33.15 and 33.6
Number of subjects: 0
Study: 2240631

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no N2O)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (N2O and no N2O)
Number of subjects: 100
Study: 4601668

Group type: EXPERIMENTAL
Intervention: BCNU (1,3 bis (2 chloroethyl) 1 nitrosourea)
Number of subjects: 44
Study: 31678410

Group type: EXPERIMENTAL
Intervention: Telepsychiatry Collaborative Care
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Telepsychiatry Enhanced Referral
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1004
Study: 31518615

Group type: EXPERIMENTAL
Intervention: Oropharyngeal airway (OPA) with mask PPV
Number of subjects: 137

Group type: COMPARATOR
Intervention: Face mask alone (control group)
Number of subjects: 137
Study: 28394933

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg+40 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg twice)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) and Ezetimibe (10 mg) twice
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25734777

Group type: EXPERIMENTAL
Intervention: Foam rolling between each lunge in sessions 1 and 2, and 5 times in 7 days between sessions 1 and 2.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group did not foam roll at all.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Foam rolling intervention group.
Number of subjects: 31
Study: 22961467

Group type: EXPERIMENTAL
Intervention: Telephone-based Enhanced Discharge Planning Program intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 22026929

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 245

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 245
Study: 19531260

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 3307
Study: 17012773

Group type: EXPERIMENTAL
Intervention: Regular exercise (10 months, 3 sessions/week)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Concurrent antioxidant supplementation (Biofrutas)
Number of subjects: 320
Study: 15320663

Group type: EXPERIMENTAL
Intervention: RER (Respiratory Exchange Ratio) warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HRR (Heart Rate Reserve) warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HP (Hydrocollator Pads) warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no warm-up)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RER warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HRR warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HP warm-up
Number of subjects: 12
Study: 11094106

Group type: COMPARATOR
Intervention: 10 mg of rizatriptan for three attacks and placebo for one attack
Number of subjects: 473
Study: 12206033

Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest Gum Care Toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest Regular Toothpaste
Number of subjects: 0
Study: 8382710

Group type: EXPERIMENTAL
Intervention: Clomipramine and maprotiline treatment
Number of subjects: 0
Study: 3786347

Group type: EXPERIMENTAL
Intervention: 0.347 g/kg ethanol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.695 g/kg ethanol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30467781

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 27391539

Group type: EXPERIMENTAL
Intervention: Biotrue with etafilcon A
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: PureMoist with galyfilcon A
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec with senofilcon A
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Biotrue, PureMoist, or RevitaLens OcuTec with galyfilcon A
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec with galyfilcon A
Number of subjects: 568
Study: 25528621

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (DHS and PFN)
Number of subjects: 0
Study: 22459434

Group type: EXPERIMENTAL
Intervention: Deep Acupuncture (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Superficial Acupuncture (SA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 0
Study: 20967307

Group type: EXPERIMENTAL
Intervention: Platform-switched abutment connections at subcrestal locations
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Straight abutment connections
Number of subjects: 282

Group type: COMPARATOR
Intervention: Straight abutment connections at supra- and subcrestal locations
Number of subjects: 282

Group type: COMPARATOR
Intervention: Overall comparison of platform-switched concept
Number of subjects: 282
Study: 18658056

Group type: EXPERIMENTAL
Intervention: Phonotactic probability
Number of subjects: 19
Study: 16401214

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg and 50 mg
Number of subjects: 150
Study: 12090608

Group type: EXPERIMENTAL
Intervention: Self-efficacy manipulation in Study 1
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Self-efficacy assessment in Study 2
Number of subjects: 187
Study: 10612406

Group type: EXPERIMENTAL
Intervention: Low-Dk hydrogel lenses (etafilcon A, Dk = 28) worn for up to 7 days and 6 nights
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-Dk hydrogel lenses (lotrafilcon A, Dk = 140) worn for up to 30 days and nights
Number of subjects: 0
Study: 8588059

Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 1957744

Group type: EXPERIMENTAL
Intervention: Predilatation with a 2 mm balloon followed by a definitive size balloon for angioplasty (group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No predilatation, only definitive size balloon for angioplasty (group 2)
Number of subjects: 54
Study: 6814355

Group type: EXPERIMENTAL
Intervention: 1.5 g of cefuroxime
Number of subjects: 358

Group type: COMPARATOR
Intervention: 4.8 x 10(6) U of aqueous procaine penicillin G intramuscularly and 1.0 g of probenecid
Number of subjects: 358
Study: 30894365

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Traditional risk factors (pulse, triglycerides, albumin excretion rate)
Number of subjects: 1441
Study: 28507269

Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose argatroban (100 μg/kg bolus followed by infusion of 1 μg/kg per minute for 48 hours)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: r‐tPA+high‐dose argatroban (100 μg/kg bolus followed by infusion of 3 μg/kg per minute for 48 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: r‐tPA alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose or high‐dose argatroban
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose argatroban
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: r‐tPA+high‐dose argatroban
Number of subjects: 90
Study: 25891339

Group type: EXPERIMENTAL
Intervention: Heparin-lidocaine combination
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alkalinized lidocaine
Number of subjects: 14
Study: 23324690

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: biofeedback assisted relaxation and stretching (BFB)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: balance exercises on a wobble board (BAL)
Number of subjects: 93

Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 93
Study: 21729717

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 18778742

Group type: EXPERIMENTAL
Intervention: Emotion suppression during an upsetting movie
Number of subjects: 66

Group type: COMPARATOR
Intervention: Natural reaction to the upsetting movie
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clinically depressed BED group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 66
Study: 17426848

Group type: EXPERIMENTAL
Intervention: Epithalamine (pineal gland peptide preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (same basic therapy)
Number of subjects: 0
Study: 14727106

Group type: EXPERIMENTAL
Intervention: Org 2766 (ACTH (4-9) analogue)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 11158450

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 9246979

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) > or = 25 at age 40
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Use of contraceptive pills
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Estrogen substitution
Number of subjects: 503
Study: 7906700

Group type: EXPERIMENTAL
Intervention: Cue exposure integrated with urge coping skills training (CET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contrast condition (CC)
Number of subjects: 40
Study: 3773577

Group type: EXPERIMENTAL
Intervention: Individual station‐designed schedules
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Straight shifts
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Regular schedule with unlimited requests for changes
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study: 29577915

Group type: EXPERIMENTAL
Intervention: Provider training intervention
Number of subjects: 576
Study: 27026043

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) + Interferon β-1a (30 μg/week)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (Interferon β-1a 30 μg/week)
Number of subjects: 95
Study: 26603251

Group type: EXPERIMENTAL
Intervention: Needling treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Callus debridement
Number of subjects: 58
Study: 24325987

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 1% alone (total volume 1 ml)
Number of subjects: 40
Study: 19967342

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + 2 nucleoside reverse transcriptase inhibitors (2NRTI) once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV) + 2NRTI once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV) + 2NRTI twice daily
Number of subjects: 0
Study: 18341724

Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 145
Study: 15726658

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg IV after EVL followed by 40 mg oral for 9 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (IV and oral)
Number of subjects: 44
Study: 12657843

Group type: EXPERIMENTAL
Intervention: Conservative fluid management (1 ml/kg/h during surgery, total 9.5 ml/kg/h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aggressive fluid management (8 ml/kg/h during surgery)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conservative fluid management
Number of subjects: 22
Study: 11013273

Group type: EXPERIMENTAL
Intervention: Amifostine (200 mg/m² intravenous daily 15 to 30 minutes before irradiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (1.8 to 2.0 Gy to doses of 50 to 70 Gy)
Number of subjects: 0
Study: 1531035

Group type: EXPERIMENTAL
Intervention: Mononine (monoclonal antibody‐purified factor IX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 10
Study: 6384617

Group type: EXPERIMENTAL
Intervention: Corinfar (40 mg daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoptin (240 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30747547

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (800 μg every 4 hours, three doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 μg every 4 hours, three doses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 200
Study: 30403271

Group type: EXPERIMENTAL
Intervention: SCP block + IV PCA tramadol
Number of subjects: 50

Group type: COMPARATOR
Intervention: GAN block + IV PCA tramadol
Number of subjects: 50
Study: 26091686

Group type: EXPERIMENTAL
Intervention: 80 kVp with 30 mL of 270 mg I/mL contrast material and iterative reconstruction (IR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 100 kVp with 60 mL of 370 mg I/mL contrast material and filtered back projection
Number of subjects: 82
Study: 24771775

Group type: EXPERIMENTAL
Intervention: S/RP treatment with endoscopic detection of calculus
Number of subjects: 30

Group type: COMPARATOR
Intervention: S/RP with tactile determination of calculus using an 11/12 explorer
Number of subjects: 30
Study: 22777367

Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension with pelvic floor muscle training
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension without pelvic floor muscle training
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SPS
Number of subjects: 169
Study: 20832439

Group type: EXPERIMENTAL
Intervention: Cereal breakfast
Number of subjects: 123

Group type: COMPARATOR
Intervention: Muffin breakfast
Number of subjects: 123
Study: 18205099

Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL) 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trandolapril (TRAN) 4 mg
Number of subjects: 30
Study: 17249272

Group type: EXPERIMENTAL
Intervention: Low Maruyama Index surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maruyama Index of Unresected Disease (MI) <5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maruyama Index (MI)
Number of subjects: 0
Study: 12010583

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/d, 3 g EPA+DHA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Olive oil (placebo, 6 g/d)
Number of subjects: 55
Study: 9536924

Group type: EXPERIMENTAL
Intervention: Intravenous lactate (40 mumol min-1 kg-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous lactate
Number of subjects: 10
Study: 8587284

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fat diet (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H.E.L.P. system
Number of subjects: 0
Study: 2571265

Group type: EXPERIMENTAL
Intervention: Medetomidine (120 micrograms)
Number of subjects: 3
Study: 31603121

Group type: EXPERIMENTAL
Intervention: Yoga + standard antiemetic therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard antiemetic therapy alone
Number of subjects: 100
Study: 29037148

Group type: EXPERIMENTAL
Intervention: PRECEDE-based education intervention (9 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical care
Number of subjects: 0